Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Second Quarter Earnings Calls, In Brief

Executive Summary

As second quarter earnings announcement shift into high gear, companies announce changes to manufacturing, progress on their drug launch efforts and their intentions to ramp up business development efforts.

You may also be interested in...



Onyx Kyprolis Launch Strategy Includes Speedy Delivery, Premium Price

Onyx is pricing new myeloma drug carfilzomib at $9,950 per cycle, 65% higher than Takeda/Millennium’s pioneering proteasome inhibitor Velcade. Launch plans include financial assistance for providers, comprehensive patient assistance program and transition for expanded access patients to commercial drug.

Teva’s New CEO Levin Urges “Fiscal, Strategic Discipline,” Reduces 2012 Guidance

In a hastily scheduled, between-quarters update, Teva takes down its 2012 guidance issued only five months ago. New CEO Jeremy Levin promises a full strategic rendering by year end, announces long-time Teva exec Allan Oberman as new head of U.S. generics and establishment of a global compliance committee.

Warner Chilcott Mum On Potential Suitors

Warner Chilcott didn’t address the elephant in the room – a potential acquisition – during its first quarter earnings call.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS054653

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel